- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05120713
Noradrenergic Activity and Attention (NAA)
September 23, 2022 updated by: Mara Mather, University of Southern California
The Influence of Noradrenergic Activity on Attentional Control in Younger and Older Adults
Older adults demonstrate increased distractibility by task-irrelevant information which contributes to general cognitive impairment.
However, it is yet unclear how changes in noradrenergic activity during aging influences attentional control.
In the current study, tonic noradrenergic activity will be increased or decreased to investigate its behavioral and neural effects on attentional control.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andy Kim, PhD
- Phone Number: 213-740-5156
- Email: andyk@usc.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90089
- Recruiting
- USC Leonard Davis School of Gerontology
-
Contact:
- Wendy Snaer
- Phone Number: 213-821-4643
- Email: wsnaer@usc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Young adults will be recruited from the student population at the University of Southern California.
Older adults will be recruited from a volunteer registry.
Description
Inclusion Criteria:
- Fluent in English
- Aged between 18-35 or 50-80
- Have normal or corrected-to-normal vision and hearing, and normal color vision
- Have a mobile phone and email address
Exclusion Criteria:
- Non-English speakers
- Currently practicing any relaxation, meditation, or breathing technique for more than an hour per week
- Have participated in studies measuring attentional capture in the past year
- Experiencing symptoms of dementia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Young Adults
Young Adults aged 18-35
|
Older Adults
Older Adults aged 50-80
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial eye-movements toward target and distractor shapes measured by an eye-tracker
Time Frame: Calculated once at the end of the 1 day experiment
|
The oculomotor suppression effect is a lower likelihood that salient display items will be the target of the initial eye movement in a visual search task compared to nonsalient display items.
Using an eye-tracker, initial fixations toward the target, salient distractor, and nonsalient distractors will be compared as a measure of attentional control.
|
Calculated once at the end of the 1 day experiment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2021
Primary Completion (Anticipated)
November 1, 2023
Study Completion (Anticipated)
November 1, 2023
Study Registration Dates
First Submitted
October 13, 2021
First Submitted That Met QC Criteria
November 3, 2021
First Posted (Actual)
November 15, 2021
Study Record Updates
Last Update Posted (Actual)
September 27, 2022
Last Update Submitted That Met QC Criteria
September 23, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
At the conclusion of the study, data in de-identified form will be shared using the Open Science Framework and/or OpenNeuro Databases which are free and open platforms for sharing and archiving scientific data.
IPD Sharing Time Frame
Data will be made available at the end of the experiment, indefinitely.
IPD Sharing Access Criteria
Data will be uploaded to scientific data archiving platforms.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom